admin

In the past few years the wearables sector has been a hive of activity, but it feels like this year things have accelerated, particularly in the realm of health and wellness. A report by Forrester Research projected that 29 percent of Americans will use wearable devices, compared with 18 percent in 2015. It predicts that wearables sales will rise from $4.2 billion in 2015 to $9.8 billion in 2021.

Bristol-Myers Squibb’s acquisition of Cardioxyl Pharmaceuticals and its prodrug used to treat heart failure earned top honors in the Mergers and Acquisitions category from Thomson Reuters’ Allicense event on June 8.

Johns Hopkins Technology Ventures and a visiting researcher from the National Institutes of Health helped put the Johns Hopkins University scientists who compose the startup in touch, which led to the creation of Cardioxyl Pharmaceuticals.

As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the exit—the sole event where company investors receive a return on their investment, either through an initial public offering (IPO) or a company sale. Unfortunately, the biotech industry’s track record on exits is disappointing. According to the National Venture Capital Association (Washington, DC), between 2005 and 2014, only one in five US biotech and medical device companies achieved liquidity after six years. And from my perspective over the past 20 years, that low success rate does not appear to be improving.

Women of the Virginia bioscience community from across the state will lead this first-ever full day event offering examples of working together to build a stronger bioscience industry, stronger companies and institutions, stronger teams and networks, and stronger individuals.  

When: Thursday, September 29, 2016 10:00AM-5:00PM

Where: Inova Center for Personalized Health 3225 Gallows Rd Fairfax, Virginia  22037 United States

Disruptors are a special type of innovator who go outside the box and attempt to change preconceived notions and practices. If you take a look at the meaning of the word, “to disrupt” means to “rupture” or break apart, and essentially disruptors do this – discarding the old ways to bring in new ones. We might even take it a step further and look at as the commonly used root of “dis” which means to “do the opposite of” – and see the idea that disruptors are “fixers” essentially putting the pieces of something broken back together. Here’s a look at three disruptors in Boston Biotech who are revolutionizing traditional pharma to radically change the ways cures are being brought about for disease.

Betamore personally invites BioHealth Innovation companies to apply to pitch and/or demo at Beta City 2016

Details

BetaCity (9/29/2016) celebrates Baltimore’s place as a global destination for entrepreneurship

Seeking the Best + Brightest to Pitch + Demo

• Pitch Competition: 3 PM – $75K+ to be awarded
• Demo Companies showcase products/services to VIP’s, investors, and the broader community
• Focus: Cybersecurity, Health IT, Other Technology

Other Notes

• In addition to the Pitch Competition + Company Demos, the event will feature a VIP Reception, Awards Ceremony, Live Music + Merrymaking

Emergent BioSolutions Inc. (EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option valued at $11.6 million over 12 months under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract option will require Emergent to conduct manufacturing runs and additional activities in support of maintaining FDA licensure of VIGIV.